Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy

Annals of Epidemiology

Volumn 19, Issue 2, 2009, Pages 96-102

  Schwartz, Gary G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical Trial; Paricalcitol; Prostate Cancer Therapy; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; ALFACALCIDOL; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCITRIOL RECEPTOR; COLECALCIFEROL; DEXAMETHASONE; DOCETAXEL; DOXERCALCIFEROL; OXYGENASE; PARICALCITOL; PLACEBO; TRANSCRIPTION FACTOR; VITAMIN D;

ADVANCED CANCER; CANCER CELL; CANCER MORTALITY; CANCER THERAPY; CELL METABOLISM; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; GEOGRAPHIC DISTRIBUTION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INTERVENTION STUDY; METABOLITE; METASTASIS INHIBITION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; VITAMIN D DEFICIENCY;

HUMANS; MALE; PROSTATIC NEOPLASMS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 58649093955     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2008.03.007     Document Type: Review

References (69)

1. de Vries, Soerjomataram I., Houterman S., Louwman M.W., and Coebergh J.W. Decreased risk of prostate cancer after skin cancer diagnosis: A protective role of ultraviolet radiation?. Am J Epidemiol 165 (2007) 966-972
2. John E.M., Schwartz G.G., Koo J., Van Den Berg D., and Ingles S.A. Sun exposure, vitamin D gene polymorphisms and risk of advanced prostate cancer. Cancer Res 65 (2005) 5470-5479
3. Holick C.N., Stanford J.L., Kwon E.M., Ostrander E.A., Nejentsev S., and Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 1990-1999
4. Schwartz G.G. The "Cocaine Blues" and other problems in epidemiologic studies of vitamin D and cancer. Nutr Rev 65 (2007) S75-S76
5. Schwartz G.G. Vitamin D and the epidemiology of prostate cancer. Semin Dialysis 18 (2005) 276-289
6. In: Kurihara M., Aoki K., and Hismamichi S. (Eds). Cancer Mortality Statistics in the World, 1950-1985 (1989), University of Nagoya Press, Nagoya, Japan
7. Yatani R., Chigusa I., Akazaki K., Stermmerman G., Welsh R., and Correa P. Geographic pathology of latent prostate carcinoma. Int J Cancer 29 (1984) 611-616
8. Thames H., Kuban D., Levy L., Horwitz E.M., Kupelian P., Martinez A., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 patients treated by external beam radiation therapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
9. Pound C.R., Parti A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
10. Sharifi N., Gulley J.L., and Dahut W.I. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
11. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351 (2004) 1502-1512
12. Schwartz G.G., and Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)?. Anticancer Res 10 (1990) 1307-1311
13. Hanchette C.L., and Schwartz G.G. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 70 (1992) 2861-2869
14. Schwartz G.G., and Hanchette C.L. UV, latitude, and prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control 17 (2006) 1091-1101
15. Miller G.J., Stapleton G.E., Ferrara J.A., Lucia M.S., Pfister S., Hedlund T.E., et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α, 25-dihydroxyvitamin D3. Cancer Res 52 (1992) 515-520
16. Moreno J., Krishnan A.V., and Feldeman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Bol Biol 97 (2005) 31-36
17. Schwartz G.G., Wang M.-H., Zhang M., Singh R.K., and Siegal G.P. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6 (1997) 727-732
18. Sung V., and Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164 (2000) 133-143
19. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S.-H., Block N.L., and Binderup L. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-Dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8 (1999) 241-248
20. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27 (2006) 32-42
21. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27 (2007) 1883-1889
22. Haddad Jr. J.G., and Hahn T.J. Natural and synthetic sources of circulating 25-Hydroxyvitamin D in man. Nature 244 (1973) 525-527
23. Holick M.F. Photobiology of vitamin D. In: Feldman D., Gloriexux F.H., and Pike J.W. (Eds). Vitamin D. 1st ed. (1997), Academic Press, San Diego, CA 33-39
24. Holick M.F. Vitamin D deficiency. N Engl J Med 19 (2007) 266-281
25. 3 and its analogs on growth control and tumorigenesis. Front Biosc 6 (2001) D820-D848
26. 3-1α-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 103 (2007) 316-321
27. Chesney R.W., Rosen J.F., Hanstra A.J., Smith C., Mahaffey K., and DeLuca H.F. Absence of seasonal variations in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J Clin Endocrinol Metab 53 (1981) 139-143
28. 3. Cancer Epidemiol Biomarkers Prev 7 (1998) 391-395
29. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9 (2000) 265-270
30. Young M.V., Schwartz G.G., Wang L., Jamieson D.P., Whitlatch L.W., Flanagan J.N., et al. The prostate 25-Hydroxyvitamin D-1α-Hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25 (2004) 967-971
31. Haussler M.R., Jurutka P.W., Hseih J.C., Thompson P.D., Selznick S.H., Hausller C.A., et al. New understanding of the molecular mechanism of receptor-mediated genomic actions of vitamin D hormone. Bone 17 (1995) 33S-38S
32. Zhuang S.-H., Schwartz G.G., Cameron D., and Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cells. Mol Cell Endocrinol 126 (1997) 83-90
33. Krill D., De Flavia P., Dhir R., Luo J., Becich M.J., Lehman E., and Getzenberg R.H. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 82 (2001) 566-572
34. Miller G.J., Stapleton G.E., Hedlund T.E., and Moffatt K.A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1 (1995) 997-1003
35. Kivineva M., Bläuer M., Syvälä H., and Tammela T. Tuohimaa. Localization of 1,25-Dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66 (1998) 121-127
36. Blutt S.E., and Weigel N.L. Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221 (1999) 89-98
37. Miller G.J. Vitamin D and prostate cancer: Biological interactions and clinical potentials. Cancer Metastasis Rev 17 (1998) 353-360
38. Hsu J.Y., Feldman D., McNeal J.E., and Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61 (2001) 2852-2856
39. Whitlatch L.W., Young M.V., Schwartz G.G., Flanagan J.N., Burnstein K.L., Lokeshwar B.L., et al. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81 (2002) 135-140
40. Chen T.C., Schwartz G.G., Burnstein K.L., Lokeshwar B.L., and Holick M.F. The use of 25-Hydroxyvitamin D3 and 19-nor-1,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6 (2000) 901-908
41. Abe E., Miyamura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cellsinduced by 1α, 25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 78 (1981) 4990-4994
42. Honma Y., Hozumi M., Abe E., Konno K., Fukushima M., Hata S., et al. 1α,25-Dihydroxyvitamin D3 and 1 α-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A 80 (1983) 201-204
43. Tobler A., and Koeffler H.P. Differentiation of human acute myelogencres leukemia cells: Therapeutic possibilities. Acta Haematol 78 Suppl 1 (1987) 127-135
44. Muindi J.R., Peng Y., Potter P., Hershberger P.A., Tauch J.S., Capozilli M.J., et al. Pharmacokinetics of high-dose oral calcitriol; Results from a phase I trial of calcitriol and paclitaxel. Clin Pharmaocol Ther.s 72 (2002) 648-659
45. Skowronski R.J., Peehl D.M., and Feldman D. Vitamin D and prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132 (1993) 1952-1960
46. Schwartz G.G., Oeler T., Uskokovic M., and Bahnson R.R. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14 (1994) 1077-1081
47. Schwartz G.G., Hill C.C., Oeler T., Becich M.J., and Bahnson R.R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46 (1995) 365-369
48. Vijayakumar S., Mehta R.R., Boerner P.S., Packianathan S., and Mehta R.G. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 11 (2005) 362-373
49. Osborn J.L., Schwartz G.G., Smith D.C., Bahnson R.R., Day R., and Trump D.L. Phase II trial of oral 1,25-Dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urologic Oncol 1 (1995) 195-198
50. Liu G., Oettel K., Ripple G., et al. Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer. Clinical Cancer Res 8 (2002) 2820-2827
51. Johnson C.S., Hershberger P.A., and Trump D.L. Vitamin D-related therapies in prostate cancer. Cancer Metast Rev 21 (2002) 147-158
52. Trump D.L., Potter D.M., Muindi J., Brufsky A., and Johnson C.S. Phase II trial of high-dose, intermittent calcitriol (1,25 Dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106 (2006) 2136-2142
53. Beer T.M., Javle M., Lam G.N., Henner W.D., Wong A., and Trump D.L. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 11 (2005) 7794-7799
54. Beer T.M., Ryan C.W., Venner P.M., Petrylak D.P., Chatta G.S., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol 25 (2007) 669-674
55. Novacea Press Release. November 05, 2007. Novacea halts ASCENT-2 trial in advanced prostate cancer. Available at: www.novacea.com/610.asp?id=136&;nav=news. Accessed April 17, 2008.
56. Beer T.M. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96 (2005) 508-513
57. Brawer M.K. Recent progress in the treatment of advanced prostate cancer with intermittent dose-intense calcitriol. Rev Urol 9 (2007) 1-8
58. Schwartz G.G., Hall M.C., Patton S., Lee W.R., Stindt D., Lovato J., and Torti F.M. A Phase I/II trial of 19-nor-1α,25-Dihydroxyvitamin D2 (paricalcitol) in advanced androgen insensitive prostate cancer. Clin Cancer Res 11 (2005) 8680-8685
59. Schnieder A., Kalikin L.M., Mattos A.C., Keller E.T., Allen M.J., Pienta K.J., et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146 (2005) 1727-1736
60. Saad F., Clarke N., and Columbel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 49 (2006) 429-440
61. Schwartz G.G. Prostate cancer, serum parathyroid hormone and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17 (2008) 478-483
62. Andress D. Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease. Drugs 67 (2007) 1999-2012
63. Gross C., Stamey T., Hancock S., and Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159 (1998) 2035-2040
64. Woo T.C.S., Jamieson J., Chander S., and Vieth R. Pilot study: Potential role of vitamin D (choecalciferol) in patients with PSA replapse after definitive therapy. Nutr Cancer 51 (2005) 32-36
65. Beer T.M., Eilers K.M., Garzotto M., Hsieh Y.-C., and Mori M. Quality of life and pain relief during treatment with calcitriol and docetazel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 100 (2004) 758-763
66. Van Veldhuizen P.J., Taylor S.A., Williamson S., and Drees B.M. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol 163 (2000) 187-190
67. Petrioli R., Pascuccu A., Francinin E., Marsili S., Sciandiviasci A., De Rubertis G., et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int 100 (2007) 775-779
68. Mould J.W., and Ward J.F. Management of the patient with a rising PSA alone. Hematol Oncol Clin N Am 20 (2006) 897-908
69. Farhan W., Wahala K., and Cross H.S. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 84 (2003) 432-429